NCT07206524View on ClinicalTrials.gov

Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation

NARecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 5, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2026

Conditions
HemodialysisThromboinflammationHemodialysis ComplicationEnd Stage Renal Disease (ESRD)
Interventions
OTHER

Hemodialysis using dialysate containing citric acid and magnesium at a concentration of 1.0 mmol/L

Change dialysate compositions being used during hemodialysis treatment in each arm.

OTHER

Hemodialysis using acetic acid dialysate with magnesium 0.5 mmol/L

Standard dialysate containing acetic acid and magnesium at a concentration of 0.5 mmol/L, used during hemodialysis sessions.

OTHER

Hemodialysis using citric acid dialysate with magnesium 0.75 mmol/L

Dialysate containing citric acid and magnesium at a concentration of 0.75 mmol/L, used during hemodialysis sessions.

Trial Locations (1)

1090

RECRUITING

Universitair Ziekenhuis Brussel, Brussels

All Listed Sponsors
collaborator

University of Rochester

OTHER

collaborator

Vrije Universiteit Brussel, Jette, Belgium

UNKNOWN

lead

Universitair Ziekenhuis Brussel

OTHER

NCT07206524 - Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation | Biotech Hunter | Biotech Hunter